Welcome to our dedicated page for Zentalis Pharmaceuticals news (Ticker: ZNTL), a resource for investors and traders seeking the latest updates and insights on Zentalis Pharmaceuticals stock.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) is a clinical-stage biopharmaceutical company focused on oncology, and its news flow centers on the development of azenosertib (ZN‑c3), an investigational WEE1 inhibitor. Company updates highlight progress in Cyclin E1-positive platinum-resistant ovarian cancer (PROC), where azenosertib is the lead program, as well as exploratory work in other tumor types and combination regimens.
Visitors to this ZNTL news page can follow announcements on the DENALI Phase 2 trial, a multi-part, registration-intent study in PROC. Zentalis uses press releases to report milestones such as completion of enrollment in DENALI Part 2a, dose confirmation plans, and expectations for topline data from Part 2, which the company states could support a potential accelerated approval pathway, subject to FDA feedback. News items also describe alignment with the U.S. Food and Drug Administration on the design of ASPENOVA, a planned Phase 3 randomized, confirmatory trial comparing azenosertib to standard-of-care chemotherapy in Cyclin E1-positive PROC.
Beyond ovarian cancer, Zentalis news covers scientific presentations and broader development activity for azenosertib, including Phase 1 data in advanced solid tumors, Cyclin E1 biomarker findings, the TETON Phase 2 trial in uterine serous carcinoma, and a Phase 1 combination study with trastuzumab deruxtecan in HER2-expressing cancers. The company also issues regular financial results and operational progress releases, detailing research and development spending, cash position, and restructuring steps intended to prioritize late-stage development of azenosertib.
Additional ZNTL headlines include corporate governance and personnel changes, such as leadership transitions in the Chief Legal Officer role, board resignations, and equity inducement grants under Nasdaq Listing Rule 5635(c)(4). Investors and observers can use this page to monitor how Zentalis links its clinical milestones, biomarker strategy and financial resources as it advances azenosertib in PROC and other tumor settings.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) announced the pricing of an underwritten offering of 10,330,000 shares of common stock at $19.38 per share, totaling approximately $200.2 million in gross proceeds. The offering is expected to close on May 18, 2022, subject to customary conditions. The net proceeds will fund ongoing and planned clinical trials, including ZN-c3 and ZN-d5, and for general corporate purposes. Zentalis aims to maintain sufficient funds for operations until the first quarter of 2025.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) announced leadership changes, appointing Kimberly Blackwell, MD, as the new CEO, succeeding Anthony Sun, MD, who will continue as CEO of joint venture Zentera Therapeutics. Blackwell, a board member with extensive oncology experience, will focus on accelerating the clinical development of lead candidates ZN-c3 and ZN-d5. Chairman Dave Johnson expressed confidence in the company’s potential, emphasizing their promising pipeline and cash runway.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced promising initial data on ZN-c3, a Wee1 inhibitor, from ongoing trials in advanced ovarian cancer and uterine serous carcinoma. The company received a $25 million equity investment from Pfizer to advance clinical development for ZN-c3 and ZN-d5. A Phase 1/2 study for ZN-d5 in relapsed AL amyloidosis has been initiated. As of March 31, 2022, Zentalis reported cash and marketable securities of $289.4 million, providing a cash runway into Q1 2024 after budget reallocations following the Pfizer investment.
Zentalis Pharmaceuticals has entered into a joint clinical development agreement with Pfizer for ZN-c3, a selective Wee1 inhibitor aimed at treating cancer. This partnership includes a $25 million investment from Pfizer through a share offering, expected to close on April 29, 2022. The funding extends Zentalis’ cash runway into Q1 2024, enabling continued clinical trials. Additionally, Pfizer's Adam Schayowitz will join Zentalis’ Scientific Advisory Board to enhance strategic clinical development. The company retains full ownership of its pipeline.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) recently presented promising clinical data for its lead candidate, ZN-c3, at the AACR Annual Meeting. The combination of ZN-c3 with chemotherapy showed an objective response rate (ORR) of 30.2% in advanced ovarian cancer patients. Additionally, in patients with uterine serous carcinoma (USC), ZN-c3 achieved a 27.3% ORR and a 90.9% disease control rate with notable tolerability. The results suggest ZN-c3's potential as a significant therapeutic option in treating advanced cancers.
Zentalis Pharmaceuticals has announced promising results from its ongoing Phase 1b trial of ZN-c3, a potential best-in-class Wee1 inhibitor, in combination with chemotherapy for platinum-resistant ovarian cancer. The treatment demonstrated an overall response rate (ORR) of 30.2% across all evaluated chemotherapy cohorts, with the highest cohort reaching 62.5%. ZN-c3 showed good tolerability, exhibiting a better safety profile than other Wee1 inhibitors. The company plans to advance to a Phase 3 trial based on these results.
Zentalis Pharmaceuticals has announced a strategic collaboration with Caris Life Sciences to enhance patient recruitment for its clinical trials. This partnership will utilize Caris’ advanced molecular profiling to identify candidates for Zentalis’ oncology studies, particularly focusing on the Wee1 inhibitor ZN-c3. Both companies aim to leverage comprehensive genomic data to improve therapeutic development. Zentalis retains full ownership of its candidates while pursuing innovative cancer treatments.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced the dosing of its first patient in a Phase 1/2 trial for ZN-d5, an oral selective BCL-2 inhibitor, targeting relapsed or refractory light chain (AL) amyloidosis. This trial (ZN-d5-003) aims to evaluate the safety, efficacy, and pharmacokinetics of ZN-d5 in patients with this rare and life-threatening condition. AL amyloidosis affects ~75,000 people globally, causing severe organ damage with limited treatment options. Zentalis aims to provide a potentially best-in-class therapy to address this unmet need.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that CEO Anthony Sun will present at the Oppenheimer Annual Healthcare Conference on March 16, 2022, at 10:00 a.m. ET. The presentation will be accessible via a live webcast on the company’s website, with an archived version available afterward. Zentalis focuses on developing small molecule therapeutics for cancer treatment, with a promising pipeline including ZN-c3 (Wee1 inhibitor), ZN-c5 (SERD), and ZN-d5 (BCL-2 inhibitor). The company operates from New York and San Diego.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) will present updated data from the Phase 1 expansion cohort of its Wee1 inhibitor ZN-c3 for uterine serous carcinoma (USC) at the AACR Annual Meeting 2022, scheduled for April 8-13 in New Orleans. The company highlights five accepted abstracts, including a mini symposium detailing ZN-c3's efficacy and safety. CEO Dr. Anthony Sun expressed optimism about the ongoing trials, noting ZN-c3's promising durability and tolerability. The company aims to explore ZN-c3's potential in combination therapies.